Hennion & Walsh Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Hennion & Walsh Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-84,259	Closed	-$2.27M	–	820
2022 Q3	$2.27M	Sell	84,259 -4,761	-5%	-$96.6K	0.15%	177
2022 Q2	$1.23M	Sell	89,020 -4,136	-4%	-$63.7K	0.08%	270
2022 Q1	$1.82M	Sell	93,156 -3,353	-3%	-$50.9K	0.1%	232
2021 Q4	$1.57M	Sell	96,509 -8,824	-8%	-$147K	0.08%	270
2021 Q3	$2.94M	Sell	105,333 -2,323	-2%	-$66.3K	0.15%	192
2021 Q2	$3.19M	Buy	107,656 +14,865	+16%	+$429K	0.17%	173
2021 Q1	$2.59M	Buy	+92,791	New	+$2.57M	0.16%	184

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hennion & Walsh Asset Management's RVNC Position: Q4 2022 in Review

Hennion & Walsh Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 84,259 shares — an estimated $2.27M sold.

Hennion & Walsh Asset Management first reported a position in RVNC in Q1 2021 and held it in 7 quarters. The position peaked at $3.19M in Q2 2021. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

Hennion & Walsh Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Hennion & Walsh Asset Management sold 84,259 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $2.27M.
Hennion & Walsh Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 7 quarters.
Hennion & Walsh Asset Management's Revance Therapeutics, Inc. position peaked at $3.19M in Q2 2021.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.